Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Asthma

Modern Standard of Care for Asthma Treatment

At a Glance

For many adults with asthma, current guidelines favor an inhaler that combines an inhaled corticosteroid with formoterol for relief rather than albuterol alone; treatment depends on approved products, asthma severity, and prescriber guidance.

For decades, the standard of care for asthma was to use two separate inhalers: a daily “controller” to manage inflammation and a “rescue” inhaler (usually albuterol) for quick relief. However, international guidelines from the Global Initiative for Asthma (GINA) have recently evolved [1]. Relying on a short-acting rescue inhaler alone is generally no longer recommended for adults due to safety concerns [2][3].

Important: Do not stop or switch your current inhalers without prescriber guidance. These strategies require specific, approved formulations depending on your country.

Why “Rescue-Only” Therapy Has Changed

A SABA (Short-Acting Beta2-Agonist), such as albuterol or salbutamol, is a bronchodilator [2]. It works by relaxing the muscles around your airways to provide quick relief, but it does nothing to treat the underlying inflammation [2].

Research has shown that using SABA alone or in high quantities (e.g., more than 3 canisters per year) is associated with a significantly higher risk of severe asthma attacks and even death in broad population studies [4][5]. While a SABA makes you feel better temporarily, airway inflammation can continue to build [2][6].

The Preferred Approach: Track 1 (MART/SMART)

The preferred approach for many adults, where approved ICS-formoterol products are available, is an anti-inflammatory reliever strategy, often referred to as MART (Maintenance and Reliever Therapy) or SMART (Single Maintenance and Reliever Therapy) [1][7].

How it Works

In this approach, you use a single inhaler that contains two medications: a low-dose Inhaled Corticosteroid (ICS) to fight inflammation and formoterol, a fast-acting but long-lasting bronchodilator [7][8].

  • As-Needed Use: In mild asthma (Steps 1–2), you use this combination inhaler only when you have symptoms. This ensures you get a dose of anti-inflammatory medicine every time you feel tight or short of breath [7][6].
  • Maintenance + Reliever: In more persistent asthma (Steps 3–5), you use the same inhaler every day as your maintenance dose and use extra puffs of it whenever you need quick relief [7][9].

In population trials, this approach has been shown to reduce the risk of severe flare-ups by 40–50% compared to using a SABA rescue inhaler alone [6][10][11].

Secondary Approach: Track 2

If Track 1 is not available or suitable, doctors use Track 2. This involves using a daily ICS-containing controller and using a separate SABA (albuterol) for rescue [7][12]. At some steps, the alternative is low-dose ICS taken whenever SABA is taken, whereas daily ICS plus SABA applies at other steps [7].

Understanding Medication Risks

While asthma medications are life-saving, they carry risks that must be managed.

The Danger of LABA-Only Therapy

You must never use a Long-Acting Beta2-Agonist (LABA)—such as salmeterol or formoterol—by itself for asthma [13]. Without the “protection” of an inhaled steroid, LABAs have been associated with paradoxical increases in asthma-related deaths [13][14]. Modern maintenance inhalers usually combine a LABA with a steroid to prevent this risk [15].

Risks of Oral Corticosteroids (OCS)

Oral steroids like prednisone are highly effective for stopping a severe attack, but they are “systemic,” meaning they affect your entire body [16]. A short, prescribed burst for an exacerbation generally should be completed as directed and does not automatically require a taper. However, prolonged, high-dose, or repeated exposure can lead to serious complications [17][18]:

  • Adrenal Suppression: With prolonged or repeated use, your body may stop producing its own cortisol, which can be dangerous if the medication is stopped suddenly without a medical plan [19][20].
  • Bone and Metabolic Health: Increased risk of osteoporosis, type 2 diabetes, and hypertension [16][21].
  • Organ Damage: Increased risk of cataracts, cardiovascular disease, and stomach ulcers [21][22].

High-Dose Inhaled Corticosteroids (ICS)

Inhaled steroids are much safer than oral pills because they go directly to the lungs [23]. Local side effects like oral thrush or a hoarse voice (dysphonia) are common, which is why rinsing your mouth and using a spacer device is recommended [24]. At very high doses, some of the medicine can still enter your bloodstream, potentially carrying a lower risk of systemic effects, so your doctor will always aim for the lowest effective dose [23][25][26].

Common questions in this guide

Why is an albuterol-only rescue inhaler no longer preferred for many adults with asthma?
Albuterol is a short-acting medicine that relaxes the airway muscles, but it does not treat the inflammation underlying asthma. Using it alone or using it frequently has been linked with a higher risk of severe asthma attacks, so many adults are offered an inhaler that also provides anti-inflammatory treatment.
What is MART or SMART asthma treatment?
MART, also called SMART, uses one inhaler containing an inhaled corticosteroid and formoterol for both regular treatment and symptom relief. Depending on asthma severity, it may be used only when symptoms occur or used every day with extra doses when needed.
What happens if an ICS-formoterol reliever is not available or suitable for me?
An alternative approach uses an inhaled corticosteroid controller and a separate short-acting rescue inhaler such as albuterol. At some treatment levels, a low-dose inhaled corticosteroid is taken whenever the rescue inhaler is used, while other levels require a daily controller.
Is it safe to use a long-acting bronchodilator by itself for asthma?
No. A long-acting bronchodilator, such as salmeterol or formoterol, should not be used alone for asthma and is generally paired with an inhaled corticosteroid. Ask your prescriber to review any inhaler that contains a long-acting bronchodilator.
What are the risks of repeated prednisone or other oral steroid courses?
Oral corticosteroids can be important for severe asthma flare-ups, but repeated, prolonged, or high-dose use can affect the whole body. Risks include reduced natural cortisol production, bone loss, type 2 diabetes, high blood pressure, cataracts, cardiovascular problems, and stomach ulcers.
How can I reduce side effects from an inhaled corticosteroid?
Rinse your mouth after using the inhaler and use a spacer when appropriate to reduce the chance of oral thrush and a hoarse voice. Your clinician should also check your technique and use the lowest dose that controls your asthma.

Get notified when new evidence is published on environmental induced asthma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (26)
  1. 1

    Update on Asthma Management Guidelines.

    Dubin S, Patak P, Jung D

    Missouri medicine 2024; (121(5)):364-367.

    PMID: 39421468
  2. 2

    The management of mild asthma.

    O'Byrne PM, Reddel HK, Beasley R

    The European respiratory journal 2021; (57(4)) doi:10.1183/13993003.03051-2020.

    PMID: 33093120
  3. 3

    Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.

    Reddel HK, Bacharier LB, Bateman ED, et al.

    American journal of respiratory and critical care medicine 2022; (205(1)):17-35 doi:10.1164/rccm.202109-2205PP.

    PMID: 34658302
  4. 4

    Exacerbation burden in patients treated as intermittent or mild-persistent asthma using short-acting β2-agonist rescue.

    Lugogo NL, Gilbert IA, Gandhi HN, et al.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2025; (134(5)):539-547.e1 doi:10.1016/j.anai.2025.02.009.

    PMID: 40010667
  5. 5

    Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America.

    Quint JK, Arnetorp S, Kocks JWH, et al.

    The journal of allergy and clinical immunology. In practice 2022; (10(9)):2297-2309.e10 doi:10.1016/j.jaip.2022.02.047.

    PMID: 35364341
  6. 6

    Is It Really Feasible to Use Budesonide-Formoterol as Needed for Mild Persistent Asthma? A Systematic Review and Meta-Analysis.

    Tong X, Liu T, Li Z, et al.

    Frontiers in pharmacology 2021; (12()):644629 doi:10.3389/fphar.2021.644629.

    PMID: 34149408
  7. 7

    Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.

    Reddel HK, Bacharier LB, Bateman ED, et al.

    Respirology (Carlton, Vic.) 2022; (27(1)):14-35 doi:10.1111/resp.14174.

    PMID: 34668278
  8. 8

    A Practical Guide to Implementing SMART in Asthma Management.

    Reddel HK, Bateman ED, Schatz M, et al.

    The journal of allergy and clinical immunology. In practice 2022; (10(1S)):S31-S38 doi:10.1016/j.jaip.2021.10.011.

    PMID: 34666208
  9. 9

    Symbicort® Maintenance and Reliever Therapy (SMART) and the evolution of asthma management within the GINA guidelines.

    Lin J, Zhou X, Wang C, et al.

    Expert review of respiratory medicine 2018; (12(3)):191-202 doi:10.1080/17476348.2018.1429921.

    PMID: 29400090
  10. 10

    Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review.

    Crossingham I, Turner S, Ramakrishnan S, et al.

    BMJ evidence-based medicine 2022; (27(3)):178-184 doi:10.1136/bmjebm-2021-111764.

    PMID: 34282031
  11. 11

    Effectiveness of Maintenance and Reliever Therapy Using Inhaled Corticosteroid-Formoterol in Asthmatics.

    Kim C, Lee Y, Lee E, et al.

    The journal of allergy and clinical immunology. In practice 2022; (10(10)):2638-2645.e3 doi:10.1016/j.jaip.2022.06.009.

    PMID: 35752435
  12. 12

    Patients' and physicians' perspectives on the burden and management of asthma: Results from the APPaRENT 2 study.

    Chapman KR, Canonica GW, Lavoie KL, et al.

    Respiratory medicine 2022; (201()):106948 doi:10.1016/j.rmed.2022.106948.

    PMID: 36029695
  13. 13

    Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed.

    Jacobson GA, Raidal S, Hostrup M, et al.

    Drug safety 2018; (41(5)):441-449 doi:10.1007/s40264-017-0631-1.

    PMID: 29332144
  14. 14

    Maintenance and Reliever Therapy in Pediatric Asthma: A Concise Review of Recent Evidence-Part I.

    Alharbi R, Alharbi AS

    Pediatric annals 2025; (54(10)):e367-e371 doi:10.3928/19382359-20250828-07.

    PMID: 41060060
  15. 15

    The US Food and Drug Administration's drug safety recommendations and long-acting beta2-agonist dispensing pattern changes in adult asthma patients: 2003-2012.

    Zhou EH, Seymour S, Goulding MR, et al.

    Journal of asthma and allergy 2017; (10()):67-74 doi:10.2147/JAA.S124395.

    PMID: 28356763
  16. 16

    Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry.

    Sweeney J, Patterson CC, Menzies-Gow A, et al.

    Thorax 2016; (71(4)):339-46 doi:10.1136/thoraxjnl-2015-207630.

    PMID: 26819354
  17. 17

    Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma.

    Dalal AA, Duh MS, Gozalo L, et al.

    Journal of managed care & specialty pharmacy 2016; (22(7)):833-47 doi:10.18553/jmcp.2016.22.7.833.

    PMID: 27348284
  18. 18

    Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management.

    Bleecker ER, Menzies-Gow AN, Price DB, et al.

    American journal of respiratory and critical care medicine 2020; (201(3)):276-293 doi:10.1164/rccm.201904-0903SO.

    PMID: 31525297
  19. 19

    Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.

    Menzies-Gow A, Gurnell M, Heaney LG, et al.

    The Lancet. Respiratory medicine 2022; (10(1)):47-58 doi:10.1016/S2213-2600(21)00352-0.

    PMID: 34619104
  20. 20

    Structured tapering of oral corticosteroids in patients with severe asthma at risk of secondary adrenal insufficiency: a case series.

    Salmerón MC, Carrillo AH, Martinez LM, Kyriakos G

    The Pan African medical journal 2025; (52()):44 doi:10.11604/pamj.2025.52.44.48421.

    PMID: 41393182
  21. 21

    Complications related to oral corticosteroid use in asthma patients: a retrospective cohort study.

    Lai CC, Chen CH, Wang YH, et al.

    Expert review of clinical pharmacology 2025; (18(4)):225-236 doi:10.1080/17512433.2025.2470834.

    PMID: 39998895
  22. 22

    Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature.

    Volmer T, Effenberger T, Trautner C, Buhl R

    The European respiratory journal 2018; (52(4)) doi:10.1183/13993003.00703-2018.

    PMID: 30190274
  23. 23

    Use of High-Dose Inhaled Corticosteroids and Risk of Corticosteroid-Related Adverse Events in Asthma Findings From the NORDSTAR Cohort.

    von Bülow A, Hansen S, Sandin P, et al.

    The journal of allergy and clinical immunology. In practice 2025; (13(7)):1609-1619.e5 doi:10.1016/j.jaip.2025.01.023.

    PMID: 39900241
  24. 24

    Effects of ICS + LABA Combination Therapy on Asthma Control: An Observational Study in Real-World Settings.

    Han P, Wang L

    Therapeutics and clinical risk management 2026; (22()):547261 doi:10.2147/TCRM.S547261.

    PMID: 41889671
  25. 25

    Inhaled Corticosteroid Exposure and Risk of Cataract in Patients with Asthma and COPD: A Systematic Review and Meta-Analysis.

    Savran O, Suppli Ulrik C

    Journal of ophthalmology 2023; (2023()):8209978 doi:10.1155/2023/8209978.

    PMID: 37899845
  26. 26

    A study protocol for a randomised controlled trial of two stepwise pharmacological treatment approaches to adult asthma: inhaled corticosteroid/formoterol reliever- versus short-acting β2-agonist reliever-based therapy - Asthma on TRACK.

    Sayers R, Cullen R, Oldfield K, et al.

    ERJ open research 2026; (12(5)) doi:10.1183/23120541.00009-2026.

    PMID: 42707905

This page explains modern asthma treatment strategies and medication safety for educational purposes, not as medical advice. Do not change inhalers or steroid medicines without guidance from your prescriber.

Guide contents environmental induced asthma
Research & Literature
03 Diagnosis and Objective Testing 05 Biologics for Severe Environmental Asthma